| This article has been cited by |
| 1 | Taking the 'Risk' out of risk-based monitoring | |
| Ashwaria Gupta |
| Perspectives in Clinical Research.2013;4(4)193 |
| [DOI] |
|
| 2 | Data-driven risk identification in phase III clinical trials using central statistical monitoring | |
| Catherine Timmermans,David Venet,Tomasz Burzykowski |
| International Journal of Clinical Oncology.2016;21(1)38 |
| [DOI] |
|
| 3 | Time-consuming and expensive data quality monitoring procedures persist in clinical trials: A national survey | |
| Lauren Houston,Allison Martin,Ping Yu,Yasmine Probst |
| Contemporary Clinical Trials.2021;103(1)106290 |
| [DOI] |
|
| 4 | Self-audits as alternatives to travel-audits for improving data quality in the Caribbean, Central and South America network for HIV epidemiology | |
| Sarah C. Lotspeich,Mark J. Giganti,Marcelle Maia,Renalice Vieira,Daisy Maria Machado,Regina Célia Succi,Sayonara Ribeiro,Mario Sergio Pereira,Maria Fernanda Rodriguez,Gaetane Julmiste,Marco Tulio Luque,Yanink Caro-Vega,Fernando Mejia,Bryan E. Shepherd,Catherine C. McGowan,Stephany N. Duda |
| Journal of Clinical and Translational Science.2020;4(2)125 |
| [DOI] |
|
| 5 | A Data-Driven Approach to Risk-Based Source Data Verification | |
| Elizabeth Nielsen,DeAnn Hyder,Chao Deng |
| Therapeutic Innovation & Regulatory Science.2014;48(2)173 |
| [DOI] |
|
| 6 | Key Considerations in the Transition to Risk-Based Monitoring | |
| Michael J. Rosenberg |
| Therapeutic Innovation & Regulatory Science.2014;48(4)428 |
| [DOI] |
|
| 7 | Evolving quality standards for large-scale registries: the GARFIELD-AF experience | |
| Keith A.A. Fox,Bernard J. Gersh,Sory Traore,A. John Camm,Gloria Kayani,Anders Krogh,Shweta Shweta,Ajay K. Kakkar |
| European Heart Journal - Quality of Care and Clinical Outcomes.2016;48(4)qcw058 |
| [DOI] |
|
| 8 | Investigation of the Factors Affecting Risk-Based Quality Management of Investigator-Initiated Investigational New-Drug Trials for Unapproved Anticancer Drugs in Japan | |
| Tomohisa Sudo,Akihiro Sato |
| Therapeutic Innovation & Regulatory Science.2017;51(5)589 |
| [DOI] |
|
| 9 | Clinical trial monitoring effectiveness: Remote risk-based monitoring versus on-site monitoring with 100% source data verification | |
| Osamu Yamada,Shih-Wei Chiu,Munenori Takata,Michiaki Abe,Mutsumi Shoji,Eri Kyotani,Chiyo Endo,Minami Shimada,Yuko Tamura,Takuhiro Yamaguchi |
| Clinical Trials.2021;18(2)158 |
| [DOI] |
|
| 10 | Heterogeneity in clinical research data quality monitoring: A national survey | |
| Lauren Houston,Ping Yu,Allison Martin,Yasmine Probst |
| Journal of Biomedical Informatics.2020;108(2)103491 |
| [DOI] |
|
| 11 | Evaluating Source Data Verification as a Quality Control Measure in Clinical Trials | |
| Nicole Sheetz,Brett Wilson,Joanne Benedict,Esther Huffman,Andy Lawton,Mark Travers,Patrick Nadolny,Stephen Young,Kyle Given,Lawrence Florin |
| Therapeutic Innovation & Regulatory Science.2014;48(6)671 |
| [DOI] |
|
| 12 | Efficient Source Data Verification Using Statistical Acceptance Sampling: A Simulation Study | |
| Rutger M. van den Bor,Bas J. Oosterman,Martinus B. Oostendorp,Diederick E. Grobbee,Kit C. B. Roes |
| Therapeutic Innovation & Regulatory Science.2016;50(1)82 |
| [DOI] |
|
| 13 | The impact of clinical trial monitoring approaches on data integrity and cost—a review of current literature | |
| Rasmus Olsen,Asger Reinstrup Bihlet,Faidra Kalakou,Jeppe Ragnar Andersen |
| European Journal of Clinical Pharmacology.2016;72(4)399 |
| [DOI] |
|
| 14 | Implementing an automated monitoring process in a digital, longitudinal observational cohort study | |
| Lisa Lindner,Anja Weiß,Andreas Reich,Siegfried Kindler,Frank Behrens,Jürgen Braun,Joachim Listing,Georg Schett,Joachim Sieper,Anja Strangfeld,Anne C. Regierer |
| Arthritis Research & Therapy.2021;23(1)399 |
| [DOI] |
|
